<DOC>
	<DOCNO>NCT01526798</DOCNO>
	<brief_summary>Chronic inflammation dialysis patient link cardiovascular mortality clinical sign symptom , like impaired response erythropoiesis-stimulating agent ( ESAs ) . This study aim demonstrate high cut-off hemodialysis effective reduce chronic inflammation thereby improve response ESAs .</brief_summary>
	<brief_title>Improvement EPO-resistance Hemodialysis Patients With Chronic Inflammation High Cut-off Hemodialysis</brief_title>
	<detailed_description>Chronic inflammation hemodialysis patient ( micro-inflammation ) cause multiple inflammatory stimulus become apparent elevated level biochemical marker CRP , IL-6 , cellular activation marker etc . Chronic inflammation link clinical sign symptom cardiovascular mortality dialysis patient . Inflamed dialysis patient show impaired response erythropoiesis-stimulating agent ( ESA ) relate reduce iron utilization ( functional iron deficiency ) elevate CRP level associate great need ESA meet hemoglobin target . If absolute iron deficiency exclude , EPO resistance likely related 'inflammatory block ' . The high molecular permeability Theralite high cut-off membrane allow significant clearance cytokine pro-inflammatory solute hemodialysis show previous trial high cut-off dialyzer . The study therefore aim demonstrate Theralite dialysis effective reduce chronic inflammation ESRD patient , thereby improve EPO responsiveness . If demonstrate , application Theralite hemodialysis may reduce morbidity mortality long term ESRD patient .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>ESRD treat chronic HD least 3 month Treatment highflux dialyzer least 3 month Age ≥18 year Receiving ESA treat anemia least 3 month Impaired ESA responsiveness indicate EPO resistance index &gt; median patient study center Transferrin saturation ( TSAT ) ≥20 % ( last routine value prior randomization ) Serum ferritin ≥100 ng/ml ( last routine value prior randomization ) Acute infection ≤4 week prior randomization HIV hepatitis infection Catheter Chronic liver disease Active cancer Known blood dyscrasia ( paraprotein abnormality ) Known bleed disorder Bleeding episode ≤12 week prior randomization Blood/red cell transfusion ≤12 week prior randomization Hypoalbuminemia define serum albumin concentration 35 g/L ( last routine value prior randomization ) Participation another clinical interventional investigation Pregnancy Inability give inform consent Planned transplantation within study period +3 month Planned intervention require hospitalization &gt; 1 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>End-Stage Renal Disease ( ESRD )</keyword>
	<keyword>chronic Inflammation</keyword>
	<keyword>EPO Resistance</keyword>
	<keyword>ESA Resistance</keyword>
	<keyword>high cut-off dialysis</keyword>
	<keyword>hemodialysis</keyword>
</DOC>